aTYR PHARMA (ATYR) Capital Leases (2022 - 2026)

aTYR PHARMA (ATYR) has reported Capital Leases for 5 consecutive years, with $36000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Capital Leases fell 94.02% year-over-year to $36000.0; the trailing twelve-month figure through Jun 2026 stood at $36000.0 (down 94.02% YoY), and the FY2025 full-year result was $259000.0, down 70.8% from the prior year.
• Capital Leases slipped to $36000.0 in Q2 2026 per ATYR's latest filing, from $151000.0 in the prior quarter.
• Across five years, Capital Leases topped out at $1.6 million in Q1 2023 and bottomed at $36000.0 in Q2 2026.
• Historically, Capital Leases has averaged $850117.6 across 5 years, with a median of $887000.0 in 2024.
• The sharpest annual moves came in 2023 and 2026: Capital Leases surged 411.74% in 2023, then sank 94.02% in 2026.
• Over 5 years, Capital Leases stood at $1.0 million in 2022, then soared by 41.81% to $1.4 million in 2023, then tumbled by 37.89% to $887000.0 in 2024, then sank by 70.8% to $259000.0 in 2025, then tumbled by 86.1% to $36000.0 in 2026.
• According to Business Quant data, Capital Leases over the past three periods registered $36000.0, $151000.0, and $259000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.